A phase II/III Study of Paclitaxel/Carboplatin alone or Combined with either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Brief description of study

This study is being done to answer the following question: Can we lower the chance of your endometrial cancer coming back and causing death by adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs?


Clinical Study Identifier: s23-00171
ClinicalTrials.gov Identifier: NCT05256225
Principal Investigator: Whitfield B. Growdon.
Other Investigators: Laura Palazzolo, Bhavana Pothuri, Kent Chan, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Carol M Lee, Edward A Jimenez, Erin Annette Reese, Jonathan B Kahn, Fabia Brisard Pierrot, Cindy Corbo, Christina Grace Wilson, Nitish Mehta, Deanna Gerber, Caitlin Elizabeth Ryan, Marina Stasenko, Kelly A Levine, Leslie R Boyd, Olivia Richardson Khouri, Victoria Helen Dowd, Kathleen M Lutz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.